(Total Views: 427)
Posted On: 02/11/2021 10:03:44 AM
Post# of 1460
Copied from IHUB’s falconer66a. Was busy this morning selling some plays in a Roth and adding more AVXL,
Fletch
falconer66a Thursday, 02/11/21 09:42:10 AM
Re: None 0
Post # of 298165
Expanded therapeutic significance, application of blarcamesine.
This bulleted paragraph In this morning's Anavex media announcement is extremely important; revealing a new, broader therapeutic significance of blarcamesine:
Quote:
Researchers at the University of California San Diego have identified the underlying cause of Alzheimer's disease in neurons. They discovered that changes in the structure of chromatin are responsible. [2] Sigma-1 Receptor (SIGMAR1), the direct target which gets activated with ANAVEX®2-73 demonstrated to restore chromatin structures. [3]
Primarily, and appropriately, the focus of blarcamesine's mechanism of action (MOA) producing its many "downstream" symptomatic improvements for the various CNS (central nervous system) diseases being targeted by Anavex has been the drug's promotion and modulation of proper, functional protein folding. That's extremely important, accounting for how the drug can restore or promote both autophagy (waste clearing and recycling in the cell) and generalized homeostasis (biochemical feedback and control of most cell processes).
Now, it being understood that the drug also favorably modulates chromatin chemistry, which is centrally involved in the proper and useful expression of genes. As noted in the paragraph, disrupted or malfunctioning chromatin structures are a cause of Alzheimer's. Consequently, the drug will be tested on any number of other diseases caused by chromatin anomalies. There is many of those, not just Alzheimer's.
The Anavex story continues to expand.
https://investorshub.advfn.com/boards/read_ms...=161733413
Fletch
falconer66a Thursday, 02/11/21 09:42:10 AM
Re: None 0
Post # of 298165
Expanded therapeutic significance, application of blarcamesine.
This bulleted paragraph In this morning's Anavex media announcement is extremely important; revealing a new, broader therapeutic significance of blarcamesine:
Quote:
Researchers at the University of California San Diego have identified the underlying cause of Alzheimer's disease in neurons. They discovered that changes in the structure of chromatin are responsible. [2] Sigma-1 Receptor (SIGMAR1), the direct target which gets activated with ANAVEX®2-73 demonstrated to restore chromatin structures. [3]
Primarily, and appropriately, the focus of blarcamesine's mechanism of action (MOA) producing its many "downstream" symptomatic improvements for the various CNS (central nervous system) diseases being targeted by Anavex has been the drug's promotion and modulation of proper, functional protein folding. That's extremely important, accounting for how the drug can restore or promote both autophagy (waste clearing and recycling in the cell) and generalized homeostasis (biochemical feedback and control of most cell processes).
Now, it being understood that the drug also favorably modulates chromatin chemistry, which is centrally involved in the proper and useful expression of genes. As noted in the paragraph, disrupted or malfunctioning chromatin structures are a cause of Alzheimer's. Consequently, the drug will be tested on any number of other diseases caused by chromatin anomalies. There is many of those, not just Alzheimer's.
The Anavex story continues to expand.
https://investorshub.advfn.com/boards/read_ms...=161733413
(2)
(0)Scroll down for more posts ▼
